Investigating the upstream signalling cues that trigger and maintain a pro-inflammatory CD4+ T cell phenotype could lead to the identification of therapeutic regimens that favour the generation and/or maintenance of self-antigen-biased, anti-tumour CD4+ T cell immunity. The gene discussed is CD4; the disease is neoplasm.